Prevalence of Weight Loss Product Use 5.5 Percent in Teens
10 Jan 2024
Clinical Result
WEDNESDAY, Jan. 10, 2024 -- Overall, 5.5 percent of adolescents use weight-loss products, with higher use among girls, according to a systematic review and meta-analysis published online Jan. 10 in JAMA Network Open.
Natasha Yvonne Hall, Pharm.B., from the School of Health and Social Development at Deakin University in Melbourne, Australia, and colleagues examined the global prevalence of nonprescription weight-loss product use in children and adolescents in a meta-analysis of 90 articles with 604,552 unique participants (56 percent of studies from North America).
The researchers found that the reported prevalence of nonprescription weight-loss product use was 5.5 percent in adolescents overall. Prevalence was 2.0, 4.4, 6.2, and 8.9 percent in the past week, past month, past year, and lifetime, respectively, when identifying use of weight-loss products in the general population. Girls had higher use of weight-loss products than boys.
"Prevalence of weight-loss product use was higher in North America compared with Asia and Europe and was higher in Asia compared with Europe," the authors write. "Given the individual and public health issues associated with adolescent use of nonprescription weight-loss products, interventions are urgently required to prevent and regulate use of weight-loss products in this population."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.